文献速递呼吸危重症与机械通气

急性呼吸窘迫综合征流行病学、诊疗模式与结局的地域经济差异:LUNG SAFE 研究解读

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study.
PubMed 文献 · Lancet Respir Med · 2017-06-15

基于 LUNG SAFE 前瞻性队列中第1–2天符合 ARDS 标准的2813例患者,按世界银行2016年国家分类分为欧洲高收入、其他高收入与中等收入三组。研究发现三组在人口学、危险因素、病情严重度、俯卧位通气与神经肌肉阻滞使用、机械通气时长、ICU 住院时长及医院生存率上存在显著差异,人均国民总收入与 ARDS 生存独立相关。

要点

  • 中低收入国家 ARDS 患者医院生存率显著低于两个高收入组。
  • 欧洲高收入国家更常用俯卧位通气与神经肌肉阻滞。
  • 其他高收入国家有创机械通气时长与 ICU 住院时长显著更短。

核心结论

  • ARDS 的严重度、临床识别、管理与患者结局存在重要地域经济差异。
  • 人均收入与 ARDS 结局独立相关。

研究设计与样本

  • LUNG SAFE 为前瞻性队列研究,2014年冬季连续4周在50个国家459个 ICU 开展。
  • 纳入2813例第1–2天符合 ARDS 标准的机械通气患者,按世界银行2016年分类分三组。

主要发现

  • 2813例中欧洲高收入组1521例(54%)、其他高收入组746例(27%)、中等收入组546例(19%)。
  • 重度 ARDS 或 PaO2/FiO2 小于150者比例在其他高收入国家显著低于另两组。
  • 俯卧位通气与神经肌肉阻滞在欧洲高收入国家显著更常用。
  • 调整后有创机械通气时长与 ICU 住院时长在其他高收入国家显著短于欧洲高收入与中等收入国家。
  • 医院生存率中等收入国家显著低于欧洲高收入与其他高收入国家。

关键数值与推荐

  • ARDS 判定为入住 ICU 第1或2天符合标准。
  • 分组依据为世界银行2016年国家分类:Europe-High、rWORLD-High、Middle。
  • 严重度分层指标包括 PaO2/FiO2 小于150。

临床怎么用

  • 应关注中低收入地区 ARDS 患者的识别与救治资源差距。
  • 在高收入地区可推广俯卧位通气与神经肌肉阻滞等已被更多使用的措施。
  • 评估 ARDS 预后时需考虑地域经济与人均收入因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). METHODS: LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the trial's secondary aims was to characterise variations in the demographics, management, and outcome of patients with ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is registered with ClinicalTrials.gov, number NCT02010073. FINDINGS: Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen in inspired air (FiO2) less than 150 was significantly lower in rWORLD-High countries than in the two other regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle countries. High gross national income per person was associated with increased survival in ARDS; hospital survival was significantly lower in Middle countries than in Europe-High or rWORLD-High countries. INTERPRETATION: Important geo-economic differences exist in the severity, clinician recognition, and management of ARDS, and in patients' outcomes. Income per person and outcomes in ARDS are independently associated. FUNDING: European Society of Intensive Care Medicine, St Michael's Hospital, University of Milan-Bicocca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Laffey JG, Madotto F, Bellani G, et al. Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study. Lancet Respir Med. 2017. PMID: 28624388. doi:10.1016/S2213-2600(17)30213-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。